BMS Reports P-I/II Study (TRIDENT-1) Results of Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
- The updated results from the registrational P-I/II study (TRIDENT-1) evaluating the safety, tolerability, PK & anti-tumor activity of repotrectinib which continued to demonstrate high response rates & durable responses, incl. robust intracranial responses along with durable efficacy benefits
- In patients with TKI-naïve & who were previously treated with one TKI and no CT, cORR as assessed by BICR was 79% & 38% with a median follow-up of 24.0 & 21.5mos.; m-DoR (34.1 & 14.8mos.); PFS (35.7 & 9.0mos.) while in patients with measurable brain metastases at baseline, intracranial ORR per BICR was 89% & 38%, respectively
- The safety profiles were manageable & consistent with prior reports at RP2D & the results will be presented at IASLC 2023 World Conference on Lung Cancer
Ref: Businesswire | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.